AI Verdict
NUTX has stronger fundamentals based on our AI analysis.
NVACW vs NUTX Fundamental Comparison
| Metric | NVACW | NUTX |
|---|---|---|
| Revenue | $100,000.0 | $875.3M |
| Net Income | $-27.3M | $70.8M |
| Net Margin | -27,256.0% | 8.1% |
| ROE | N/A | 21.5% |
| ROA | -641.3% | 7.7% |
| Current Ratio | 0.18x | 3.41x |
| Debt/Equity | N/A | 0.09x |
| EPS | $-2.29 | $10.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
NVACW vs NUTX: Frequently Asked Questions
Is NVACW or NUTX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), NUTX has stronger fundamentals. NVACW is rated STRONG SELL (95% confidence) while NUTX is rated STRONG BUY (85% confidence). This is not investment advice.
How does NVACW compare to NUTX fundamentally?
Profusa, Inc. has ROE of N/A vs Nutex Health Inc.'s 21.5%. Net margins are -27,256.0% vs 8.1% respectively.
Which stock pays higher dividends, NVACW or NUTX?
NVACW has a dividend yield of N/A or no dividend while NUTX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in NVACW or NUTX for long term?
For long-term investing, consider that NVACW has STRONG SELL rating with 95% confidence, while NUTX has STRONG BUY rating with 85% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about NVACW vs NUTX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For NVACW vs NUTX, the AI consensus favors NUTX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.